海昆肾喜联合贝那普利治疗慢性肾脏病Ⅲ期的临床观察

Clinical Observation of Haikun Shenxi Combined with Benazepril in the Treatment of Chronic Kidney Disease at Phase Ⅲ

目的:观察海昆肾喜联合贝那普利治疗慢性肾脏病(CKD)Ⅲ期的临床疗效和安全性。方法:将CKDⅢ期患者70例,随机均分为对照组(贝那普利15mg·d-1)和治疗组(海昆肾喜2粒,tid;贝那普利15mg·d-1),2组疗程均为12周。观察患者临床症状改善情况,并检测治疗前后血浆白蛋白(Alb)、血尿素氮(BUN)、血肌酐(Scr)、内生肌酐清除率(Ccr)、总胆固醇(TC)、甘油三酯(TG)、24h尿蛋白定量(UTP)及不良反应。结果:治疗组总有效率(85.3%)明显高于对照组(63.6%,P<0.05)。2组治疗后UTP与治疗前比较,差异有统计学意义(P<0.05),且治疗组较对照组降低更显著(P<0.05)。治疗组Alb、Ccr较治疗前明显上升(P<0.05),TG、TC、BUN、Scr较治疗前明显下降(P<0.05),且上述指标与对照组比较,差异均有统计学意义(P<0.05)。2组均未见严重不良反应发生。结论:海昆肾喜联合贝那普利不仅可以改善CKDⅢ期患者临床症状,还能降低血脂,有效延缓CKDⅢ期患者肾功能进展,且安全性较好。

OBJECTIVE： To observe the clinical efficacy and safety of Haikun shenxi combined with benazepril in the treatment of chronic kidney disease（CKD）at phase Ⅲ. METHODS： 70 patients with phase III CKD were randomly divided into control group （benazepril 15 mg. d^-1） and treatment group （Haikun shenxi 2 pellets, bid; benazepril 15 mg. d^-1） which was treated with Hai- kun shenxi and benazepril for 12 weeks. The clinical symptoms of 2 groups were observed, and the changes of serum albumin （Alb）, blood urea nitrogen （BUN）, serum creatinine （Scr）, creatinine clearance rate （Ccr）, cholesterol（TC）, triglyceride（TG）, urinary total protein （UTP） and ADRs in 2 groups were determined before and after treatment respectively. RESULTS： The total ef- fective rate of treatment group （85.3%） was higher than that of control group （63.6%） （P〈0.05）. There was statistical signifi- cance in UTP between 2 groups before treatment （P〈0.05）, the decrease of UTP in treatment group was more significant than con- trol group （P〈0.05）. Alb and Ccr in treatment group increased significantly after treatment, compared with before treatment （P〈 0.05）. TC, TG, BUN, Scr declined greatly, compared with before treatment （P〈0.05）. There was statistical significance in above index between 2 groups （P〈0.05）. There were no serious ADRs found. CONCLUSION： Haikun shenxi combined with benazepril is not only beneficial to the recovery of clinical symptoms, but also to reduce blood lipid and postpone the deteriorating of renal function of the patients with phase Ⅲ CKD with low ADRs.